Eiger BioPharmaceuticals Inc
NASDAQ:EIGR
Intrinsic Value
Eiger BioPharmaceuticals, Inc. engages in the development and commercialization of foundational therapies for Hepatitis Delta Virus. [ Read More ]
The intrinsic value of one
EIGR
stock under the Base Case scenario is
118.27
USD.
Compared to the current market price of 3.8 USD,
Eiger BioPharmaceuticals Inc
is
Undervalued by 97%.
Eiger BioPharmaceuticals Inc's market capitalization is 5.6m USD.
EIGR stock price is 3.8 USD.
EIGR stock price (3.8 USD) is 97% less than its Intrinsic Value (118.27 USD).
EIGR. Open DCF Valuation
EIGR stock price (3.8 USD) is 97% less than its Relative Value (118.27 USD). Open Relative Valuation
EIGR.
EIGR's Revenue has grown by 17% over the past 12 months.
EIGR's ROE (Return on Equity) has significantly decreased in the last 3 years from -24% to -367%, and is approaching profitability.
EIGR's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -1 376% to -614%, and is approaching profitability.
EIGR's long-term liabilties (53m USD) exceed its long-term assets (39m USD).
EIGR's short-term liabilties (53m USD) exceed its short-term assets (38m USD).
EIGR has negative Operating Income for the last twelve months.
EIGR has negative Net Income for the last twelve months.
EIGR's ROE (Return on Equity) for the past 12 months is negative and is equal to -367%.
EIGR's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -614%.
EIGR has positive Gross Profit for the last twelve months.
EIGR has negative Free Cash Flow for the last twelve months.
EIGR has negative three-year average ROE (Return on Equity): -118%. The company is not efficient at transforming stockholders' equity into net income.
EIGR has negative three-year average ROIC (Return on Invested Capital): -612%. The company is not efficient at using invested capital to generate operating income.
EIGR's D/E (Debt to Equity) is very low and is equal to 0.
EIGR's Altman Z-Score is very low and is equal to -25.31.
EIGR doesn't generate enough operating income (-72m USD) to safely cover interest payments on its debt (4m USD).
Fundamental Analysis
Eiger BioPharmaceuticals Inc
Balance Sheet Decomposition
Eiger BioPharmaceuticals Inc
| Current Assets | 37.8m |
| Cash & Short-Term Investments | 25.4m |
| Receivables | 1.7m |
| Other Current Assets | 10.7m |
| Non-Current Assets | 987k |
| PP&E | 627k |
| Other Non-Current Assets | 360k |
| Current Liabilities | 53.3m |
| Accounts Payable | 2.1m |
| Accrued Liabilities | 10.1m |
| Other Current Liabilities | 41.1m |
Earnings Waterfall
Eiger BioPharmaceuticals Inc
|
Revenue
|
15.8m
USD
|
|
Cost of Revenue
|
-16k
USD
|
|
Gross Profit
|
15.8m
USD
|
|
Operating Expenses
|
-87.5m
USD
|
|
Operating Income
|
-71.8m
USD
|
|
Other Expenses
|
-3.2m
USD
|
|
Net Income
|
-75m
USD
|
Free Cash Flow Analysis
Eiger BioPharmaceuticals Inc
EIGR Profitability Score
Profitability Due Diligence
Eiger BioPharmaceuticals Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
Score
Eiger BioPharmaceuticals Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
EIGR Solvency Score
Solvency Due Diligence
Eiger BioPharmaceuticals Inc's solvency score is 31/100. The higher the solvency score, the more solvent the company is.
Score
Eiger BioPharmaceuticals Inc's solvency score is 31/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
EIGR Price Targets Summary
Eiger BioPharmaceuticals Inc
Ownership
EIGR Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
EIGR Price
Eiger BioPharmaceuticals Inc
| Average Annual Return | -29.98% |
| Standard Deviation of Annual Returns | 46.81% |
| Max Drawdown | -100% |
| Market Capitalization | 5.6m USD |
| Shares Outstanding | 1 477 300 |
| Percentage of Shares Shorted | 3.22% |
Company Profile
Eiger BioPharmaceuticals Inc
Country
Industry
Market Cap
Dividend Yield
Description
Eiger BioPharmaceuticals, Inc. engages in the development and commercialization of foundational therapies for Hepatitis Delta Virus. The company is headquartered in Palo Alto, California and currently employs 27 full-time employees. The company went IPO on 2014-01-30. The firm is focused on the development of therapies to treat and cure Hepatitis Delta Virus (HDV), the severe form of viral hepatitis, and other serious diseases. Its clinical product candidates include Lonafarnib (LNF) for HDV, Peginterferon Lambda (lambda) for HDV and Covid-19, Avexitide in Post-Bariatric Hypoglycemia (PBH) and Avexitide in Congenital Hyperinsulinism (CHI). Lambda is a late-stage, type III, interferon (IFN), that stimulates immune responses that are critical for the development of host protection during viral infections. Avexitide is a peptide, which is developing as a treatment for congenital hyperinsulinism (HI). The company is also developing lambda as an out-patient treatment for patients with mild and moderate COVID-19. The firm is also developing Avexitide as a treatment for post-bariatric hypoglycemia (PBH).
You don't have any saved screeners yet
